MicroRNAs (miRNAs) are evolutionary conserved small noncoding RNAs that regulate gene expression by mediating posttranscriptional silencing of target genes. Since miRNAs are involved in fine-tuning of physiological responses, they have become of interest for diagnosis and therapy of a number of diseases. Moreover, the role of dysregulated miRNAs in maintaining the malignant phenotype has profound implications for cancer therapy. We will review the best defined cellular miRNAs and changes in their expression profile in hepatocellular carcinoma (HCC). Cellular miRNAs can also be released into the circulation, and these miRNAs are detected in most body fluids. Circulating miRNAs are associated with HCC and are possible biomarkers. Finally, by affecting several clinically relevant targets, artificially increasing or decreasing the expression level of a given miRNA offers fascinating therapeutic perspectives. We will therefore highlight recent developments in miRNA-based gene therapy with a focus on their therapeutic potential for HCC. Ó
Introduction
Hepatocellular carcinoma (HCC) is the major primary liver cancer, which is the fifth most common cause of cancer worldwide [1] , with about 750,000 patients globally reported each year (International Agency for Research on Cancer, IARC). An estimated 80-90% of all HCCs arise from the cirrhotic liver. Major risk factors are chronic viral hepatitis B (HBV) or C (HCV), which account for 80-90% of all HCCs worldwide [2] , and alcoholic and non-alcoholic steatohepatitis-associated liver cirrhosis. Liver cancer is the third cancer-related cause of death, with an annual mortality of about 700,000 persons globally. Low survival is attributed to late diagnosis, resistance to treatment, tumor recurrence, and metastasis, hence stressing the need for novel diagnostics and therapeutics. Specific miRNAs have been shown to be involved in various biological processes, including development, cellular proliferation, apoptosis, and oncogenesis [3] . The finding that individual miRNAs may target several hundred genes, and that a large percentage of mRNAs may be subject to regulation by miRNAs, further underscores the emerging importance of miR-NA-mediated regulation [4, 5] . Here, we review miRNA biogenesis and its alterations as well as miRNA polymorphisms linked to HCC, miRNA detection methods, the association of cellular and circulating miRNAs expression patterns with HCC, their predicted target genes, and discuss the diagnostic and therapeutic potential of some miRNAs.
either monocistronic -a single miRNA gene behind a promoteror polycistronic -expressed from one transcript as a cluster containing several miRNA gene products e.g. the miR-1792 miRNA polycistron [7] . Depending on their genome position, globally about 50% of all miRNA genes are intragenic, the so-called mirtrons -likely to be regulated through their host gene -but they can also be located in intergenic regions i.e. likely to be independent transcriptional units [8] . The pri-miRNA is then cleaved by the microprocessor complex which consists of the nuclease Drosha and the double-stranded RNA-binding protein DiGeorge syndrome critical region gene 8 (DGCR8) into a precursor miRNA (pre-miRNA) (Fig. 1B) . This 70-nt long pre-miRNA is exported to the cytoplasm via Exportin-5 ( Fig. 1C) where it will be cleaved by another nuclease, Dicer, into an imperfect miRNA-miRNA ⁄ duplex (Fig. 1D ) of 18-25 nucleotides [9] . While the passenger strand (miRNA ⁄ , in black in Fig. 1 ) is commonly degraded, the mature miRNA guide strand (in red in Fig. 1 ) is loaded into the RNA-induced silencing complex (RISC; Fig. 1E ) where further regulations will be undertaken, depending on the level of complementarity between the miRNA and its target in the 3 0 untranslated region (3 0 UTR) of the messenger RNA (mRNA). In case of perfect complementarity, the mRNA will be cleaved by RISC and degraded; in case of imperfect complementarity, translation will be repressed [10] . In mammals, decreased mRNA levels were shown to be preceding protein decrease in 84% cases [11] . Functional target sites within the mRNA usually consist of a 6-7-nt long sequence which is complementary to the miRNA sequence, followed by an adenosine, the so-called miRNA ''seed'' sequence. Target mRNAs end up in cytoplasmic processingbodies (P-bodies) where they are degraded [12] . Interestingly, other recently discovered classes of non-coding RNAs can also participate in regulation of gene expression and/or have been associated with HCC. Ender et al. showed that the small nucleolar RNA (snoRNA) ACA45 is processed by Dicer into RNAs of miRNAlike length (20-to 25-nt long) that will bind to Argonaute proteins (Ago), moreover they demonstrated the miRNA-like function of ACA45 by luciferase reporter assays [13] . Yang et al. identified a long non-coding RNA (lncRNA) named High Expression in Hepatocellular Carcinoma (lncRNA-HEIH) that is differentially expressed in HCC and whose expression level is positively associated with tumor recurrence and negatively correlated with survival. In addition, they showed that shRNA-mediated downregulation of lncRNA-HEIH significantly inhibited the growth of tumors in a xenograft mouse model [14] .
Regulation of miRNA processing in association with HCC Mature miRNA processing involves multiple steps, and each can potentially be affected, having an impact on the resulting net amount of produced mature miRNA. The process starts with the pri-miRNA transcription, which can be regulated by transcription factors or genes that are dysregulated in HCC, and that bind to the corresponding sequence located upstream in the promoter region. For example, the oncogenic transcription factor c-Myc binds upstream of miR-17 and upregulates the transcription of the miR-17-92 tumor-promoting polycistron [15] . Interestingly, c-Myc similarly binds upstream of other miRNAs, e.g. let-7 and miR-26a, this time by repressing their transcription, indicating that cellular miRNAs can have opposite functions in cancer development [16] . In a similar fashion, the tumor-suppressor gene p53 upregulates the transcription of miR-34, resulting in cell cycle arrest and apoptosis [17] [18] [19] [20] . Epigenetic mechanisms e.g. histone deacetylation and DNA methylation can result in miRNA silencing. For instance, Furuta et al. showed that methylation of miR-124 and miR-203 genes in HCC cell lines silenced their expression [21] . The next step of miRNA processing, when Dicer cleaves out the mature miRNA, can be affected in HCC, e.g. Dicer expression is altered in many cancers [22] . This results in miRNA dysregulation and as a consequence, in an abnormal gene expression that may lead to cancer phenotype. Finally, the stability of the mature miR-NA molecule can be affected by differential polyadenylation modifications. miR-122, a liver-specific miRNA, is selectively 3 0 adenylated, which will result in a higher stability in the liver while it will be destabilized in fibroblasts due to poly(A) polymerase GLD-2 depletion [23, 24] .
Key Points 2
• miRNA polymorphisms have been associated with increased risk of developing hepatocellular carcinoma (HCC)
• miRNA processing is altered in HCC
• Hepatic miRNAs are dysregulated in HCC and this involved in HCC onset and progression
• Cellular miRNAs can be released into the circulation, and circulating miRNA levels are also affected in HCC results in changes in the expression profile of target genes miRNA polymorphisms
Besides the possible alterations in the miRNA processing, miRNA polymorphisms can also be associated with an increased risk of HCC. A miRNA polymorphism consists of a single nucleotide polymorphism (SNP) in the miRNA gene. Although rare, a SNP in a miRNA can affect its transcription, processing, or target recognition. Since binding of a miRNA to its mRNA target is limited only to the seed sequence, even one nucleotide change would result in a different group of genes that would be regulated. Recently, two groups of investigators have described that a variant of miR196a-2 is positively associated with HCC susceptibility, in two populations of distinctive ethnical background [25, 26] . Yet, the field of HCC-associated miRNA polymorphisms and their relevance to disease progression as a result of regulation of different pools of genes is only starting to develop.
Detection of miRNAs
Since miRNAs are involved in fine-tuning of physiological responses, they have become of interest for diagnosis and therapy of a number of diseases; nevertheless, reliable miRNA detection is a key requirement. Currently, the three most commonly used detection methods are microarray, RT-qPCR and next-generation sequencing (NGS). Much less common is the use of Northern blot, in situ hybridization and bead-based flow cytometry. Microarray is based on annealing of DNA oligonucleotides to the homologous sequences, on a microchip. Main advantages are the relatively low price and the high throughput, but the method has a low sensitivity and specificity, i.e. miRNAs with similar sequences (miRNA families) can hybridize with the same probe. The use of DNA locked nucleic acid (LNA) oligonucleotides in microarrays ensures a greater specificity by increasing the melting temperature. In addition, the sensitivity has also been increased [27] . miRNA RT-qPCR is based on a stem-loop primer binding to the mature miRNA during the reverse transcription, making it a highly specific technique that can distinguish 1-nt differences between related miRNAs [28] . Although preamplification step sometimes required before the RT-qPCR can induce some bias and underestimate the concentration of lowly expressed miRNAs, this method is more sensitive than microarray. Despite its higher cost, it is currently the method of choice for validation of miRNA signatures. NGS is a high-throughput technology that provides global information on all miRNAs in a certain sample. Costs are much higher and data analysis is more laborious, but NGS provides quantitative data, allows miRNA discovery and provides data on miRNA polymorphisms and differential processing. Finally, the nCounter developed by Nanostring Technologies (Seattle, WA) is based on annealing of a fluorescent barcode probe followed by single molecule imaging, without preamplification step, offering high sensitivity and specificity. This technology offers high-throughput when using up to 800 multiplexed targets.
Key miRNAs dysregulated in HCC
Dysregulation of miRNAs in cancer has been repeatedly described, e.g. deregulated miRNAs in prostate, bladder, and kidney cancer [29] , breast cancer [30] , colon cancer [31] . Importantly, miRNAs are predominantly downregulated in tumor tissue [32] . Hepatocellular carcinoma is no exception and various HCC-specific miRNA signatures have been described (Table 1) . Screens of clinical samples are qualitatively heterogenic, firstly because of the variability in the technical procedure, from method of sampling (surgery or biopsy), time to and procedure of freezing, RNA isolation, to method of detection. Most miRNA screens are done using miRNA RT-qPCR, but some publications report microarray and NGS as described in Table 1 . Secondly, the disease etiology is a significant factor of variation. This should be taken into account when pooling data, as the patient group can have a single etiology (alcohol or viral) or mixed etiologies (alcohol plus viral). Thirdly, the stage of the disease should also be considered, although miRNA dysregulations occur from an early stage [33] , it is not clear how miRNA expression changes during disease progression. Finally, the control tissue used for normalization is also of importance, as it can be the healthy liver from patients with a different pathology or no known pathology, or non-tumoral liver tissue from the same patient, i.e. with the same underlying liver disease (e.g. cirrhosis, viral infection), the latter allowing to look only at intra-individual changes [34] . Nevertheless, dysregulation of several key miRNAs appears to be common to different screens, as described in Table 1 .
Use of miRNAs in molecular classification of HCC and in prognosis
Key miRNAs are affected in HCC, and different dysregulation patterns can be used to discriminate tumors based on molecular characteristics. For instance, downregulation of miR-375 has been associated with b-catenin mutation, and downregulation of miR-107 with hepatocyte nuclear factor 1a (HNF1a) [35] . Toffanin et al. recently proposed a miRNA-based classification of HCC in three subclasses: the wingless-type MMTV integration site, interferon-related, and proliferation subclasses [36] . Such miR-NA-based determination of molecular subclasses of HCC could allow subtype-specific treatment. miRNA signatures can also be used to determine disease prognosis, e.g. Budhu et al. identified a 20-miRNA signature as a predictor of survival and recurrence [37] . In addition, low tumoral miR-26 expression has been associated with high interleukin-6 (IL6) expression, and shorter survival [38] ; Ji et al. showed a better response of these tumors to interferon therapy compared to tumors with high miR-26 levels [38] . It hence appears that miRNA profiling may play a crucial role in the clinic, not only for HCC classification and subtype-specific treatment allocation, but also for prognosis. balance between miRNA and gene expression level. In the context of HCC, miRNAs can act either as oncogenes, by inducing progression of a cell to cancer, or as tumor-suppressors, by preventing cell progression to cancer miRNAs ( Fig. 2 , in red) repressing the expression of oncogenic targets; when downregulated in HCC, a higher expression of their targets is allowed, hence promoting the malignant phenotype. Alternatively, upregulation of oncogenic miRNAs (Fig. 2 , in green) in HCC will cause downregulation of their gene targets, again promoting the malignant phenotype.
Targets of tumor-suppressing miRNAs downregulated in HCC
Being downregulated in HCC, tumor-suppressor miRNAs cause upregulation of oncogenic target genes, stimulate and/or increase cellular mechanisms such as cell proliferation, cell cycle regulation, cell migration and invasion, apoptosis, and hence participate in the establishment and maintenance of the cancer phenotype, as described in Fig. 2 . Cyclin G1 (CCNG1) is one of the most well-characterized targets of miR-122 [39] . However, miR-122 also targets the anti-apoptotic BCL-W [40] and ADAM17 (a disintegrin and metalloprotease family 17) involved in metastasis [41] . Additional validated miRNA targets are described in Fig. 2 .
Targets of oncogenic miRNAs upregulated in HCC
Oncogenic miRNAs are upregulated in HCC, thus causing downregulation of target genes and decrease of cell mechanisms such as apoptosis, which eventually leads to onset and progression of the disease, as described in Fig. 2 . Overall, less miRNAs are upregulated than downregulated in cancer [32] . miR-221 targets the cyclin-dependent kinase inhibitors CDKN1B/p27 [42] and CDKN1C/p57 [43] , which results in an increase in the G1 to S phase shift and induces cell growth. Another target of miR-221 is the pro-apoptotic BMF of the BCL-2 family [44] , therefore in HCC, BMF downregulation inhibits apoptosis. Enforced miR-221 expression also induces downregulation of DNA damage-inducible transcript 4 (DDIT4), leading to modulation of the mTOR pathway [45] and of the tumor suppressors thymidylate synthase (TIMP3) and PTEN [46] , which results in enhanced cell migration.
Circulating miRNAs

Origin and clinical relevance of circulating miRNAs
Recently it has been described that miRNAs are found in many body fluids including plasma [47] . Vesicles (microvesicles or exosomes) released from cells to the circulation do contain miRNAs [48] . A positive correlation between cellular and exosomal miRNAs levels was reported for a subset of 8 miRNAs, both presenting a profile significantly different in ovarian cancer compared to benign ovarian disease [49] . Circulating miRNAs can therefore be considered representative of some pathological conditions. Moreover, their accessibility and high stability in the circulation system [50] make them perfect biomarkers, especially for surveillance of early stage, pre-symptomatic diseases in at-risk patients. For example, a serum diagnostic test based on a 34-miRNAs signature, could diagnose early stage lung cancer with 80% accuracy [51] . This study underscores the remarkable potential of circulating miRNAs in early, pre-symptomatic disease diagnosis.
Key Points 3
• Circulating plasma miRNA signatures may provide a novel diagnosis method for early, pre-symptomatic HCC patients, and may prove useful as prognosis biomarkers
• for HCC therapy by potentially affecting several targets with only one miRNA; yet more research is required in particular concerning possible off-targeting
The field of miRNA-based gene therapy holds promise
Circulating miRNAs associated with HCC
As described above, many miRNAs are dysregulated in HCC. Therefore, it is anticipated that circulating miRNAs are also affected during HCC progression. A few studies reported altered levels of circulating miRNAs in association with HCC (Table 2 ). For instance, the serum level of miR-221 was shown to be 4.8-fold elevated in HCC patients [52] . Additionally, high level of miR-221 positively correlated with cirrhosis, tumor size and tumor stage, and negatively correlated with overall survival. These promising results should be validated in a larger patient cohort; nevertheless, miR-221 serum level monitoring could be of clinical relevance as a potential diagnosis tool and biomarker of treatment efficacy. Indeed, no optimal blood tumor marker has been developed so far, the performance of a-fetoprotein (AFP), Lens culinaris agglutinin-reactive AFP (AFP-L3) and des-ccarboxyprothrombin (DCP) [53] is limited in a surveillance mode and for early HCC detection. In addition, the American Association for the Study of Liver Diseases (AASLD) Practice Guidelines (July 2010) discarded AFP for surveillance and diagnosis. Therefore, there is a need for novel markers that would combine the less invasiveness of a blood test and serve as a reliable early detection method. miRNAs definitely have this potential because not only they can be detected in plasma, but their sensitivity and stability are suitable for a clinical setting. Depending on the method, as little as one copy can be detected (see paragraph on detection). Nevertheless, appropriate controls should be used, since HCC is most often accompanied by viral infection, cirrhosis, or other underlying liver conditions. Therefore, in order to assess the HCC-specificity of a miRNA, it is critical to ensure not only an age-and gender-matched control group but they should also be matched for etiology and severity of underlying liver disease. For instance, the miRNA profile of three patient groups was compared: 105 patients with HCC (19.1% HBV, 62.9% HCV, 17.1% other etiology), 107 with chronic liver disease (CLD; 7.5% HBV, 55.1% HCV, 37.4% other etiology) and 71 normal controls [54] . In another study, miR-16 and miR-199a levels were decreased in serum and significantly associated with HCC [54] . miR-16 was more sensitive as HCC detection marker than AFP, DCP, and AFP-L3. Combination of miR-16 with AFP, DCP, and AFP-L3 allowed detection of 92.4% HCC cases with a high specificity (78.5%), and interestingly, it could detect tumors 63 cm with the same sensitivity (92.4%). This research demonstrates the feasibility of plasma markers for diagnosis of HCC. Circulating miRNAs could therefore be used as a first-line testing in HCC patients if they would outperform the currently used tumor markers. The discovery of circulating miRNAs offers interesting clinical perspectives but this field of research is quite recent and more work has to be done. It remains to be established which miRNA can sensitively and reliably be correlated with the presence of HCC at early stages of disease development and prognosis.
Cellular miRNAs as therapeutic targets in HCC
Potential of miRNA-based gene therapy
RNAi was identified in Caenorhabditis elegans in 1998 by Fire and Mello [55] and in mammalian cells in 2001 by Tuschl [56] . Since then, RNAi has generated increasing interest and publications in diverse research areas. The combination of RNAi with the latest developments in the field of gene therapy which rendered it safer, and the delivery more efficient, opens the door to novel therapeutic perspectives. Among the many possibilities currently investigated, the use of cellular miRNAs as therapeutic agents is one of the most promising from a clinical point of view. Many miRNAs are downregulating genes that are highly relevant to HCC and therefore contribute to disease progression. Because a single miRNA could potentially affect several clinically relevant targets, artificially increasing or decreasing the expression level of a given miRNA offers interesting therapeutic perspectives. Such therapy could even be combined with local chemotherapy via the transarterial route (transarterial chemoembolization, TACE) to increase the treatment effectiveness. Nevertheless, because a miRNA can affect the expression of several downstream targets, modulating the expression of a miRNA of interest could also lead to undesirable off-target effects.
miRNA-based gene therapy for HCC
The main question raised by RNAi-based gene therapy is the delivery of the effector molecule, which should preferably be controllable, sustained and tissue-specific. Several groups have chosen for non-viral delivery of synthetic miRNA molecules. miRNA mimics or miRNA antagomirs can be repeatedly delivered locally or systemically and that would cause transient suppression of target gene expression. To prevent rapid degradation of naked molecules, miRNAs are modified or conjugated to improve stability or target delivery to a specific tissue. They can be incorporated into stable nucleic acid lipid particles (SNALPs), a lipid bilayer coated by polyethylene glycol (PEG) which will protect them from degradation, prevent immunostimulation and facilitate their uptake in endosomes [57] . Similarly, 2 0 O-methyl modifications increase the stability of synthetic molecules, additionally preventing off-targeting [58] . Mimicking the external viral protein structure, virus-like particles (VLP) can also be used for synthetic miRNA delivery, yet they are not suitable for all applications since they stimulate the immune response [59] . However, VLP vehicles take advantage of the natural virus tropism, e.g. HBV in the liver, and can efficiently mediate hepatic gene transfer [60] . Finally, miRNA conjugation to HDL, LDL or cholesterol will also lead to hepatic uptake [61] . However, even with the described improvements, miRNAs would need to be delivered monthly or bimonthly. Landford et al. inhibited miR-122 expression in 4 chimpanzees using SPC3649 LNA-modified oligonucleotides. Because miR-122 stimulates HCV RNA accumulation, miR-122 inhibition leads to an efficient suppression of HCV replication and stable reduction of viremia in chimpanzees [62] . A phase I trial for SPC3649 (Miravirsen from Santaris Pharma) showed that SPC3649 was well-tolerated and the drug is now in phase II trial. This approach holds promise for HCV patients and has the advantage that it should not allow the development of viral escape variants. Nevertheless Li et al. reported that mutations in miR-122 binding site in HCV 5 0 UTR reduced SPC3649 treatment efficacy [63] . This indicates that viral escape could still be possible.
Alternatively, gene therapy using virally-delivered miRNAs is desirable when chronic and genetic diseases need to be treated. Viral delivery indeed can offer sustained expression after single dosing, however, in clinical perspective, it raises several questions concerning safety. Pri-miRNA can be delivered as an expression cassette using different types of viral vectors. The advantages and disadvantages of the viral vectors used in gene therapy clinical trials are summarized in Table 3 . Briefly, the main disadvantage of lentivirus and retrovirus is their integration into the host genome, which raises safety issues. On the contrary, adeno-associated virus (AAV) genome remains episomal, which gives it an advantageous safety profile. However, the episomal presence of AAV questions its relevance for cancer therapy. Up to now, adenovirus has been widely used in HCC gene therapy clinical trials [64] [65] [66] [67] [68] [69] [70] , as well as Vaccinia virus [71] . Despite the fact that many virus-delivered ''classical'' gene therapy products have been developed for HCC and are currently progressing through clinical trial phases, no virus-delivered miRNA-based gene therapy has been tested in clinical trials yet. Indeed, more research still needs to be done to carefully evaluate potential risks of this approach. Kota et al. showed that self-complementary AAV serotype 8 (scAAV8)-delivery of miR-26a in tumorbearing tet-o-myc; LAP-tTA mice restored miR-26a expression [72] . Re-expression of miR-26a specifically reduced cancer cell proliferation, induced tumor-specific apoptosis, and suppressed tumorogenesis. At 3 weeks post-transduction, most liver tissue in the control group was replaced with tumor while in 8 out of 10 mice of the treated group no or small tumors only were found [72] . This research demonstrated for the first time the therapeutic potential of restoring the expression of a dysregulated miRNA in the liver. Additional advantages of this approach are that the miRNA is well-tolerated, given that it is only downregulated in tumor cells, and therefore only tumor cells are affected. However, its significance in patients still needs to be determined. With the first successes of RNA agents in clinical trials, it becomes clear that miRNAs and their inhibitors hold a great potential as therapeutics for different cancers including HCC.
Conclusions
It is now well-established that miRNAs are key players in many various biological processes, including development, cellular proliferation, apoptosis, and oncogenesis [3] . In HCC, miRNAs have aberrant processing and expression profiles, in addition, the profile of circulating miRNAs is also affected, which renders them potential biomarkers, with possible applications in diagnosis, especially for early, pre-symptomatic disease, and prognosis of HCC. One miRNA may target several genes that are involved in the development and maintenance of the HCC phenotype. Therefore, miRNA-based gene therapy offers promising perspectives compared to classical gene therapy for HCC. An additional advantage of miRNAs is that since they encode no protein, they are generally not immunogenic. However, activation of Toll-like receptors (TLRs), involved in initiation of inflammatory responses to pathogens, can occur, as reviewed by O'Neill et al. [73] , indicating that unanticipated off-target effects can occur in a clinical setting. For instance, the let-7 family regulates the expression of TLR4 and this can create off-target effects [74] . A positive aspect of gene therapy for HCC is that the delivery route seems not to be questioned, up to now direct imaging-guided intratumoral injection has been the most used strategy in clinical trials, but tumorselective intra-arterial administration could be a good alternative [70] . In HCC, combination of classical and miRNA-based therapies appears a desirable goal. First, chemo-or radiation therapy can improve gene transfer efficiency and transgene expression [75, 76] . Second, in the case of combined chemo-and gene-therapies, a direct co-injection of both via the intravenous route used for the TACE procedure, could be suitable, offering a gene therapy delivery route already clinically approved and in practice. The discovery of miRNA-mediated gene regulation as a fundamental post-transcriptional mechanism increases the complexity of cancer genetics. However, understanding the molecular mechanisms by which miRNAs regulate development and tumorogenesis may lead to novel concepts in the diagnosis and treatment of cancer.
Besides the fact that miRNAs have shown promising results in pre-clinical studies, miRNA-based gene therapy is not yet suitable for routine clinical practice.
